BioLineRx Reports First Patient Dosing with Motixafortide in P-II Study for the Treatment of Pancreatic Cancer (PDAC)
Shots:
- BioLineRx has dosed the first patient with motixafortide, CXCR4 inhibitor, in the P-II (CheMo4METPANC) study, conducted in collaboration with Columbia University, for the treatment of PDAC
- The P-II (CheMo4METPANC) study investigates motixafortide + cemiplimab + gemcitabine + nab-paclitaxel vs gemcitabine and nab-paclitaxel alone for treating 1L metastatic pancreatic cancer patients (n=108)
- Furthermore, the results, as of Jul 2023, revealed that PRs in the pilot phase were seen in 7/11 patients of which 5 had confirmed PR during the data cut off, hepatic metastatic lesion was resolved in 1 patient & stable disease was seen in 3 patients which resulted in a DCR of 91%
Ref: BioLineRx | Image: BioLineRx
Related News:- BioLineRx’s Aphexda (motixafortide) + Filgrastim Receives the US FDA’s Approval for Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
